Latest Research And Development News

Amcor plc reported a 10% increase in net sales for fiscal 2025 following its merger with Berry Global Group, Inc., yet net income fell 30% amid significant integration expenses and higher debt costs. The company aims to unlock $530 million in synergies by 2028 while navigating global economic and operational risks.

The GPT Group reports strong interim earnings and operational growth for the first half of 2025, highlighted by a new $1 billion logistics partnership and ongoing development projects.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.

Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.

Lithium Universe Limited has acquired exclusive global rights to Macquarie University's innovative electrochemical silver extraction technology, promising a cleaner, more efficient way to recycle silver from solar panels while preserving valuable silicon wafers.

Anteris Technologies reported solid clinical progress with 130 patients implanted with its DurAVR heart valve and is gearing up for its pivotal PARADIGM trial with 79 qualified sites worldwide. The company also strengthened its leadership with two new board members amid ongoing FDA engagement.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

VEEM Limited has renewed a six-year, $65 million contract to supply critical components for Australia's Collins Class submarines, reinforcing its long-standing defence partnership and projecting stronger financial performance in FY26.

Iress Limited reported a robust first half of 2025 with strong earnings growth and reduced leverage, driven by core business strength and strategic divestments. The company is poised to capitalize on regulatory tailwinds and technology demand in wealth and trading sectors.

Iress Limited has reported a 19% increase in underlying earnings per share for its continuing business in the first half of 2025, completing a major transformation and reaffirming its full-year guidance despite revenue pressures from divestments.